FSE$CVAC
CureVac NV · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Headline financials
Revenue & EPS history
CureVac · Revenue · Quarterly
€38.9M
Q2 2020
Revenue by segment
CureVac · €1.25M total across 2 segments · Q2 2025
- CRISPR collaboration (Switzerland)€1.06M—85.1%
- GSK collaboration (Belgium)€186K—14.9%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports
+1.1%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+5.3%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+12.9%
Q3 2020
Best reaction
-11.2%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -1.7% | +5.8% | -16.0% | |
| Q2 2025 | -0.2% | -0.9% | -3.1% | |
| Q1 2025 | +4.9% | +9.5% | +31.8% | |
| Q4 2024 | -4.0% | +19.5% | +28.8% | |
| Q3 2024 | -1.4% | -8.7% | +15.0% | |
| Q1 2024 | -5.6% | -7.6% | -17.3% | |
| Q4 2023 | -11.2% | -2.4% | +54.3% | |
| Q3 2023 | +0.4% | +1.5% | +4.5% | |
| Q2 2023 | -5.3% | -3.7% | -15.6% | |
| Q1 2023 | +5.5% | +2.4% | +19.1% | |
| Q4 2022 | -5.3% | -4.0% | +23.1% | |
| Q3 2022 | +5.3% | -1.4% | -15.4% | |
| Q2 2022 | -8.3% | -14.0% | -27.3% | |
| Q1 2022 | +2.2% | +1.9% | -20.9% | |
| Q4 2021 | +6.9% | +8.1% | +17.7% | |
| Q3 2021 | +6.0% | — | — | |
| Q2 2021 | +12.7% | — | — | |
| Q4 2020 | +6.5% | — | — | |
| Q3 2020 | +12.9% | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro